Marcus Schulz Sells 3,000 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFSGet Rating) CRO Marcus Schulz sold 3,000 shares of the company’s stock in a transaction on Wednesday, January 18th. The shares were sold at an average price of $25.04, for a total transaction of $75,120.00. Following the sale, the executive now owns 44,975 shares of the company’s stock, valued at approximately $1,126,174. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Marcus Schulz also recently made the following trade(s):

  • On Wednesday, January 11th, Marcus Schulz sold 258 shares of BioLife Solutions stock. The shares were sold at an average price of $21.94, for a total transaction of $5,660.52.
  • On Thursday, November 10th, Marcus Schulz sold 40 shares of BioLife Solutions stock. The shares were sold at an average price of $23.16, for a total transaction of $926.40.
  • On Friday, October 28th, Marcus Schulz sold 400 shares of BioLife Solutions stock. The shares were sold at an average price of $21.76, for a total transaction of $8,704.00.

BioLife Solutions Price Performance

BLFS opened at $24.45 on Monday. The company has a quick ratio of 2.76, a current ratio of 3.68 and a debt-to-equity ratio of 0.06. BioLife Solutions, Inc. has a 12 month low of $10.40 and a 12 month high of $31.11. The company has a fifty day simple moving average of $20.35 and a 200 day simple moving average of $21.18. The stock has a market cap of $1.05 billion, a P/E ratio of -9.86 and a beta of 1.75.

BioLife Solutions (NASDAQ:BLFSGet Rating) last released its quarterly earnings data on Wednesday, November 9th. The medical equipment provider reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03). BioLife Solutions had a negative net margin of 67.70% and a negative return on equity of 7.50%. The firm had revenue of $40.75 million during the quarter, compared to the consensus estimate of $41.63 million. On average, research analysts expect that BioLife Solutions, Inc. will post -0.63 EPS for the current year.

Analyst Ratings Changes

BLFS has been the subject of several recent research reports. Stephens dropped their target price on shares of BioLife Solutions to $31.00 in a research report on Wednesday, November 16th. StockNews.com upgraded shares of BioLife Solutions to a “sell” rating in a research report on Monday, November 21st.

Hedge Funds Weigh In On BioLife Solutions

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. D.A. Davidson & CO. boosted its stake in BioLife Solutions by 50.0% in the 2nd quarter. D.A. Davidson & CO. now owns 30,000 shares of the medical equipment provider’s stock worth $414,000 after purchasing an additional 10,000 shares during the period. New York State Teachers Retirement System boosted its stake in BioLife Solutions by 160.0% in the 2nd quarter. New York State Teachers Retirement System now owns 68,082 shares of the medical equipment provider’s stock worth $940,000 after purchasing an additional 41,900 shares during the period. Maryland State Retirement & Pension System boosted its stake in BioLife Solutions by 15.9% in the 3rd quarter. Maryland State Retirement & Pension System now owns 13,938 shares of the medical equipment provider’s stock worth $317,000 after purchasing an additional 1,914 shares during the period. Conestoga Capital Advisors LLC boosted its stake in BioLife Solutions by 42.2% in the 2nd quarter. Conestoga Capital Advisors LLC now owns 81,547 shares of the medical equipment provider’s stock worth $1,126,000 after purchasing an additional 24,182 shares during the period. Finally, RMB Capital Management LLC boosted its stake in BioLife Solutions by 8.0% in the 2nd quarter. RMB Capital Management LLC now owns 350,966 shares of the medical equipment provider’s stock worth $4,847,000 after purchasing an additional 25,986 shares during the period. 89.82% of the stock is owned by institutional investors and hedge funds.

BioLife Solutions Company Profile

(Get Rating)

BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

See Also

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.